ArticleHaematologica2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.Clinical medicine & research · 2020Trial
- Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.Blood advances · 2026Article
- Myeloproliferative Neoplasms: Challenging Dogma.Journal of clinical medicine · 2024Review
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Review
- International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.Virchows Archiv : an international journal of pathology · 2023Review
- Molecular prognostication in Ph-negative MPNs in 2022.Hematology. American Society of Hematology. Education Program · 2022Article
- Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.Leukemia · 2022Article
- Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2022Review
- Review
- Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.International journal of molecular sciences · 2021Review
- Is there a gender effect in polycythemia vera?Annals of hematology · 2021Review
- Review
- Standard care and investigational drugs in the treatment of myelofibrosis.Drugs in context · 2019Review
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.Blood cancer journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.